Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis-Reference-Cited by-同舟云学术

Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis

Published:2024-05 Issue: Volume:202 Page:113977
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Untch Michael^ORCID,Pérol David,Mayer Erica L.,Cortes Javier^ORCID,Nusch Arnd,Cameron David,Barrios Carlos^ORCID,Delea Thomas,Danyliv Andrii,Mishra Namita,Gupta Rhea,Pathak Purnima,Fasching Peter A.

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Reference42 articles.

1. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Cardoso;Ann Oncol,2019

2. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017

3. Clinical endpoints in oncology - a primer;Delgado;Am J Cancer Res,2021

4. NCCN clinical practice guidelines in oncology;Breast Cancer,2022

5. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0;Tolaney;J Clin Oncol,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequently asked questions on surrogate endpoints in oncology-opportunities, pitfalls, and the way forward;eClinicalMedicine;2024-09

2. CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms;European Journal of Cancer;2024-08

3. Ribociclib plus Endocrine Therapy in Early Breast Cancer;New England Journal of Medicine;2024-06-20